A plastic surgeon I know performs a large number of explant procedures. Recently, he described what he sometimes sees when implants that have been in place for ten, fifteen, or twenty years are removed.
The surfaces are not always clean. Some are coated in a slick film. The surrounding capsule may appear discolored or inflamed. Occasionally, he told me, the internal fluid would have signs of mold or fungal contamination with discoloration.
That conversation stayed with me because I see the other end of this clinical story: women with profound fatigue, brain fog, diffuse pain, poor sleep, chemical sensitivity, and a growing list of symptoms. Sometimes they have breast implants. I long suspected that those implants could have been a source of their mold exposure, as illogical as that seemed on the surface.
What mold exposure can do
Mold spores are everywhere. Most people inhale them daily without consequence because the immune system clears them efficiently.
The situation changes in persistently water-damaged buildings. A slow leak behind drywall, a flooded basement, or a contaminated HVAC system can support organisms that produce mycotoxins.
Mycotoxins are not the same as mold allergy. They are biologically active compounds capable of influencing cellular membranes, mitochondrial function, inflammatory signaling, and immune regulation.
Not everyone exposed becomes ill. Susceptibility appears to depend on genetics, prior infections, chemical burden, barrier integrity, immune reserve, and the duration and intensity of exposure.
In susceptible patients, symptoms may include fatigue, cognitive dysfunction, sleep disruption, headaches, migratory pain, autonomic symptoms, and new sensitivities to foods, medications, chemicals, or odors.
These patients are often told that their routine laboratory testing is normal and that their symptoms are caused by stress, anxiety, hormones, or aging.
That dismissal is not justified but neither is diagnostic certainty where certainty does not exist.
A breast implant is not biologically inert
An implant may be sterile when it is placed. It does not necessarily remain biologically sterile over the following decade.
Implant surfaces can become colonized by biofilms: organized microbial communities that adhere to a surface and surround themselves with a protective matrix. Dental plaque is a familiar example. The difference is that an implant biofilm sits inside the chest, inaccessible to cleaning and in continuous contact with the immune system.
Researchers have repeatedly identified bacterial communities on breast implants and within the surrounding capsules. Studies have found that implant-associated microbial populations can be diverse and may vary within different regions of the same capsule.
Biofilm has also been implicated as one potential contributor to capsular contracture, the painful tightening and hardening of the tissue surrounding an implant. Capsular contracture remains multifactorial, but the association between bacterial colonization, biofilm formation, and abnormal capsule development is supported by a growing body of evidence.
A persistent microbial community on a foreign body can generate inflammatory signals for years.
Are breast implants contaminated with mold?
Clinically, I have seen enough suspicious findings to believe this question deserves serious investigation.
I have cared for women with breast implants who present with the same combination of fatigue, cognitive dysfunction, chemical sensitivity, immune dysregulation, and fungal or mold-related findings that I see in other environmentally exposed patients.
Those clinical observations matter. But they are not the same as laboratory confirmation.
Material found around an implant can include bacterial biofilm, fibrin, inflammatory debris, degraded tissue, altered silicone gel, or discolored fluid. Some of it may resemble mold during surgery.
The published evidence confirms that fungal contamination of breast implants can occur. Most documented infections involve yeast, particularly Candida, rather than the environmental molds typically associated with water-damaged buildings.
Filamentous molds, including Aspergillus, Penicillium, and Curvularia, have also been reported, but these cases appear uncommon. Reviews of implant infections suggest that fungal cases occur most often in saline implants and tissue expanders, where the fluid-filled environment may be more favorable to fungal growth.
The clearest evidence involves saline implants. Because saline devices are filled during surgery, contamination can potentially be introduced during the filling process. A puncture or loss of implant integrity may also provide an opportunity for organisms to enter.
The more dramatic claim—that environmental mold commonly grows inside an intact silicone gel implant—has not been demonstrated. Experimental work suggests that fungal spores and hyphae do not readily penetrate an intact silicone shell. Published examples of fungus growing inside an implant have more often involved saline devices, punctured filling ports, damaged implants, or contamination introduced during surgery.
But the absence of demonstrated mold inside intact silicone implants does not make silicone biologically irrelevant. Silicone implants carry a different set of potential immunogenic and inflammatory concerns. The body forms a fibrous capsule around the device because it recognizes the implant as foreign. Macrophages, lymphocytes, fibroblasts, and other immune cells participate in this foreign-body response.
Silicone particles or gel may also reach the surrounding tissue through rupture or microscopic gel bleed. These materials can be taken up by macrophages, accumulate within the capsule, and migrate to regional lymph nodes. In susceptible patients, this may contribute to persistent local inflammation or broader immune activation.
There are therefore at least two distinct, but potentially overlapping, questions:
Can an implant become colonized by bacteria, yeast, or mold?
And:
Can the implant material and the surrounding foreign-body response create chronic immunologic strain even when no fungus is present?
The available evidence suggests that both may occur in certain patients, although their frequency, mechanisms, and clinical significance remain incompletely understood.
My clinical position is that fungal and mold contamination is biologically plausible, has been documented, and may be missed in some patients. But it should not be presumed simply because an implant or capsule looks abnormal.
At the same time, a negative fungal evaluation does not necessarily mean the implant is irrelevant to the patient’s immune dysfunction. Silicone exposure, bacterial biofilm, foreign-body inflammation, rupture, gel bleed, and individual immune susceptibility may each contribute to the overall burden.
When suspicious material is found during explant surgery, the most useful next step is appropriate sampling for fungal culture, bacterial culture, histopathology, and, when available, bacterial and fungal molecular testing.
How I evaluate these patients
Because no single test can settle the question, I look for convergence: multiple independent findings that point toward chronic environmental immune provocation, impaired immune surveillance, or persistent microbial burden.
The useful question is not simply, “Is there mold in the body?”
It is: Does this patient’s immune system appear to have been chronically provoked, and does it still have the capacity to contain the exposures it encounters?
Environmentally driven immune dysfunction
I look for evidence of disrupted immune tolerance, barrier injury, cross-reactive antibody production, and abnormal immune responses to environmental antigens.
These findings do not prove mold illness or implant-related illness. They may, however, show that the immune system has been under sustained environmental pressure.
Antibodies to chemicals
Chemical compounds can bind to human proteins and change how the immune system recognizes them. These altered protein-chemical complexes are known as haptens.
Solvents, formaldehyde, bisphenols, plastic-associated compounds, and other environmental chemicals may participate in this process. Antibodies directed against these complexes can provide a footprint of an environmentally provoked immune system.
This does not necessarily identify the exact source of exposure. It can, however, help reveal a broader pattern of lost tolerance and immune reactivity.
Viral reactivation
Declining immune surveillance can allow latent viruses to reactivate.
Epstein-Barr virus, human herpesvirus 6, cytomegalovirus, and other persistent viruses may become more active when T-cell and natural killer cell function deteriorate.
Viral reactivation can then become an independent source of fatigue, cognitive dysfunction, autonomic symptoms, and inflammation.
In some patients, the original environmental or implant-related burden may no longer be the only driver of illness. The loss of viral containment may become a second, self-sustaining source of immunologic strain.
Fungal dysbiosis of the gut
The gastrointestinal tract may provide another source of chronic fungal exposure and immune activation.
Candida overgrowth and broader disruption of the intestinal mycobiome may increase local inflammation and contribute to the production or absorption of fungal metabolites.
This may help explain why some patients remain symptomatic even after leaving or remediating a water-damaged building. The original exposure may have altered the gut ecosystem, allowing an inflammatory and microbial process to continue after the external source is gone.
No single finding proves the diagnosis.
But when chemical antibodies are elevated, natural killer cell function is impaired, latent viruses have reactivated, and fungal dysbiosis is present, the findings begin to form a coherent biological picture.
“The implants may be one contributor to the patient’s immunologic burden. They may not be the only one.”
Where I have landed
Breast implant biofilms are real and likely underappreciated as a source of chronic immune stimulation.
Fungal contamination is also real, but the evidence suggests that it is less common and more context-specific than social media implies. Saline implants, compromised devices, surgical contamination, and significant immunosuppression appear to carry the highest risk.
Silicone implants present a related but distinct concern. Even when mold is not present, silicone exposure, gel bleed, foreign-body inflammation, bacterial biofilm, and individual immune susceptibility may contribute to chronic immunologic strain in a subset of patients.
I would not tell a woman that her implants gave her mold illness unless there were compelling microbiological findings to support that conclusion.
But I would take her symptoms seriously, assess the state of immune dysfunction, and look carefully for the sources of immunologic strain or inflammation that may be sustaining it.
That framework—identifying impaired immune resilience and systematically removing the environmental, microbial, chemical, and inflammatory burdens contributing to it—has worked well in my practice.
Remaining open to the possibility that multiple environmental factors can converge in the same patient is what led me to consider breast implants as one potential contributor.
Hopefully, further research will clarify how often fungal colonization occurs, which patients are most susceptible, and when an implant becomes clinically relevant to systemic illness.
References
Ajdic D, Zoghbi Y, Gerth D, Panthaki ZJ, Thaller S. The relationship of bacterial biofilms and capsular contracture in breast implants. Aesthetic Surgery Journal. 2016;36(3):297-309. doi:10.1093/asj/sjv177.
Crowe SA, Simister RL, Spence JS, et al. Microbial community compositions in breast implant biofilms associated with contracted capsules. PLoS One. 2021;16(4):e0249261. doi:10.1371/journal.pone.0249261.
Cook J, Finch K, Duffy K, et al. Characterizing the microbiome of the contracted breast capsule using next-generation sequencing. Aesthetic Surgery Journal. 2021;41(4):440-447. doi:10.1093/asj/sjaa129.
Del Pozo JL, Tran NV, Petty PM, et al. Pilot study of association of bacteria on breast implants with capsular contracture. Journal of Clinical Microbiology. 2009;47(5):1333-1337. doi:10.1128/JCM.00096-09.
Kainer MA, Keshavarz H, Jensen BJ, et al. Saline-filled breast implant contamination with Curvularia species among women who underwent cosmetic breast augmentation. Journal of Infectious Diseases. 2005;192(1):170-177. doi:10.1086/430613.
Saray A, Kaygusuz S, Kisa U, et al. Fungal growth inside saline-filled implants and the role of injection ports in fungal translocation: an in vitro study. Plastic and Reconstructive Surgery. 2004;114(5):1170-1178.
Horch RE, Stark GB, Beier JP, et al. Aspergillus fumigatus spores are not able to penetrate an intact silicone shell used in breast implants. Aesthetic Plastic Surgery. 2020;44(3):801-806. doi:10.1007/s00266-019-01585-z.
Kuhn N, Dela Cruz C, Denning D, et al. Rare presentation of breast implant infection and capsular contracture caused by Penicillium species. Eplasty. 2022;22:e29.
Taritsa IC, et al. Breast implant silicones and B cell-mediated immune responses. Journal of Immunology and Regenerative Medicine. 2024;25:100092. doi:10.1016/j.regen.2024.100092.
Papanikolaou GE, et al. Early systemic immune response to silicone breast implants: a prospective analysis of peripheral lymphocyte populations. Journal of Clinical Medicine. 2025.
Kawamoto MM, Page EH. Notes from the field: use of unvalidated urine mycotoxin tests for the clinical diagnosis of illness—United States, 2014. Morbidity and Mortality Weekly Report. 2015;64(6):157-158.
New York Post. I had my breast implants removed after battling hives, nausea, pain and anxiety—turns out they were full of mold. Published July 6, 2026.
This article is for education and discussion and is not medical advice. The hypothesis that fungal colonization of breast implants causes systemic mycotoxin illness has not been established. Decisions regarding implant removal, culture testing, or reconstruction should be made with a qualified surgeon and the patient’s treating clinicians.